In clinical trials, we observed 1 out of 7 grade III–V CRS patients in 17patients with B-cell ALL developed Acute myelofibrosis (AMF) post CD19 CAR-T cells therapy. This evidence concerns the gene CD19 and congenital rubella syndrome.